Pasithea Therapeutics Corp SEC Filings

Pasithea Therapeutics Corp. (KTTA) director Lawarence Steinman reported a stock option grant. The Form 4 shows a stock option for 242,913 shares of common stock at an exercise price of $0.715, granted on 10/24/2025 and expiring on 10/23/2035. The option was awarded under the company’s 2023 Stock Incentive Plan.

The shares underlying the option vest in full on the one-year anniversary of the grant date, provided he remains a director through that date, and will fully vest upon a Change in Control as defined in the plan.

Pasithea Therapeutics (KTTA) disclosed a Form 4 showing CFO Daniel Schneiderman received a stock option for 317,266 shares at an exercise price of $0.715 per share on 10/24/2025, expiring 10/23/2035. The award vests 33% on the one-year anniversary of grant, with the balance vesting in equal quarterly installments over the next two years, subject to continuous service. The option fully vests upon a Change in Control as defined in the plan. Vested options may be exercised for up to three years after service ends, except in cases of termination for cause.

Pasithea Therapeutics (KTTA)42,913 stock options at an exercise price of $0.715 per share, with a transaction date of 10/24/2025 and direct ownership.

The options vest in full on the one-year anniversary of the grant date, provided the individual remains a director through that date, and will fully vest upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan. The options expire on 10/23/2035.

Pasithea Therapeutics (KTTA) disclosed that CEO and director Dr. Tiago Reis Marques was granted a stock option to purchase 493,341 shares of common stock at an exercise price of $0.715 per share. The grant date was 10/24/2025 and the option expires on 10/23/2035.

The option vests 33% on the one-year anniversary of grant, with the remainder vesting in equal quarterly installments over the following two years, subject to continued service. The option fully vests upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan, and vested portions may be exercised for up to three years following termination of continuous service (except for cause).

Pasithea Therapeutics (KTTA) reported a director’s stock option award. On 10/24/2025, Dr. Emer Leahy acquired a stock option42,913 shares of common stock at an exercise price of $0.715 per share, expiring on 10/23/2035. The filing shows 42,913 derivative securities beneficially owned directly after the transaction. According to the company’s 2023 Stock Incentive Plan, the shares underlying the option vest in full on the one-year anniversary of the grant if the individual remains a director, and fully vest upon a Change in Control.

Pasithea Therapeutics (KTTA) filed a Form 4 reporting a director stock option grant. On 10/24/2025, the director received an option to purchase 42,913 shares of common stock at an exercise price of $0.715 per share under the company’s 2023 Stock Incentive Plan. The option expires on 10/23/2035 and will vest in full on the one-year anniversary of the grant date, provided the director remains on the board through that date; the award will fully vest upon a Change in Control as defined in the plan.

Pasithea Therapeutics (KTTA) updated executive and director compensation. The Board raised the CEO’s base salary to $533,000 and set his target bonus at 55% of base pay. The CFO’s base salary increased to $391,000 with a 40% target bonus. These cash changes are retroactive to January 1, 2025.

Equity awards were granted at an exercise price of $0.715 per share as of October 24, 2025: the CEO received options for 493,341 shares, the CFO 317,266 shares, and certain employees an aggregate of 352,266 shares. Each vests 33% on the one‑year anniversary, then quarterly over the next two years, and fully upon a Change in Control.

Director pay was adjusted to conserve cash: the Audit Chair retainer increased by $5,000 to $15,000, while the Board Chair’s annual cash compensation was reduced from $100,000 to $35,000 effective October 1, 2025. Each non‑employee director received options for 42,913 shares at $0.715, vesting in full after one year, with Change in Control acceleration. Prof. Steinman’s consulting payments were reduced from $25,000 per quarter to $1.00 per quarter effective October 1, 2025, and he received a one‑time option for 200,000 shares at $0.715, vesting after one year.